Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kathleen Allor

Physician Assistant, Medical Troy, MI Physician Assistant

NPI 1336119361 CMS profile 10470392

44201 Dequindre Rd, Troy, MI 48085

Open in the dashboard

General payments

$15,226

718 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathleen Allor of Troy, MI is reported in the CMS Open Payments database as having received $15,226 across 718 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,048 163
2024 General $3,633 144
2023 General $3,226 172
2022 General $2,259 123
2021 General $2,060 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathleen Allor
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kathleen Allor were reported at $4,048. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kathleen Allor Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,060 $156 $41–$563 $132
2022 $2,259 $185 $55–$649 $149
2023 $3,226 $199 $58–$717 $160
2024 $3,633 $206 $62–$740 $164
2025 $4,048 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $3,057 83 payments
  2. Janssen Biotech, Inc. $1,283 70 payments
  3. Merck Sharp & Dohme Corporation $681 29 payments
  4. Incyte Corporation $629 35 payments
  5. Genentech USA, Inc. $629 45 payments
  6. AstraZeneca Pharmaceuticals LP $626 30 payments
  7. AbbVie, Inc. $621 27 payments
  8. Eisai Inc. $482 35 payments
  9. Lilly USA, LLC $454 21 payments
  10. Amgen Inc. $449 23 payments
  11. Other $6,315 320 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,008 681 payments
  2. Long term medical supply or device loan $2,030 22 payments
  3. Education $1,189 15 payments
Products named General payments · program years 2021–2025
  1. KISQALI $2,607 54 payments
  2. DARZALEX $861 42 payments
  3. KEYTRUDA $681 29 payments
  4. VENCLEXTA $496 20 payments
  5. Lenvima $482 35 payments
  6. Doptelet $361 16 payments
  7. OPDIVO $357 25 payments
  8. VERZENIO $341 16 payments
  9. TECVAYLI $335 23 payments
  10. IMBRUVICA $292 14 payments
  11. Other $11,102 632 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

844

Median for Physician Assistant: 241

Drug cost

$2,554,601

Median for Physician Assistant: $4,110

Branded share of claims

30.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Revlimid Lenalidomide Brand 34 $503,844
Pomalyst Pomalidomide Brand 17 $380,197
Imbruvica Ibrutinib Brand 33 $361,918
Ibrance Palbociclib Brand 21 $324,954
Calquence Acalabrutinib Maleate Brand 22 $300,723
Kisqali Ribociclib Succinate Brand 17 $287,270
Lenalidomide Generic 23 $271,673
Promacta Eltrombopag Olamine Brand 11 $75,599
Eliquis Apixaban Brand 42 $28,270
Anastrozole Generic 192 $9,441

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 63 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
$1,122 17 —
KEYTRUDA
$155 — —
VERZENIO
$115 — —
VENCLEXTA
$111 — —
Lenvima
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 63 with Patron

Records

718 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record